AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.-论文-万方医学网

第一作者： Moshe,Elkabets

第一单位： Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.

作者： Moshe,Elkabets ^[1] ; Evangelos,Pazarentzos ^[2] ; Dejan,Juric ^[3] ; Qing,Sheng ^[4] ; Raphael A,Pelossof ^[5] ; Samuel,Brook ^[1] ; Ana Oaknin,Benzaken ^[6] ; Jordi,Rodon ^[6] ; Natasha,Morse ^[1] ; Jenny Jiacheng,Yan ^[2] ; Manway,Liu ^[4] ; Rita,Das ^[4] ; Yan,Chen ^[4] ; Angela,Tam ^[4] ; Huiqin,Wang ^[4] ; Jinsheng,Liang ^[4] ; Joseph M,Gurski ^[3] ; Darcy A,Kerr ^[3] ; Rafael,Rosell ^[7] ; Cristina,Teixidó ^[8] ; Alan,Huang ^[4] ; Ronald A,Ghossein ^[9] ; Neal,Rosen ^[10] ; Trever G,Bivona ^[2] ; Maurizio,Scaltriti ^[11] ; José,Baselga ^[12]

作者单位： Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. ^[1] Division of Hematology and Oncology, Department of Medicine, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, 600 16th Street, San Francisco, CA 94158, USA. ^[2] Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA. ^[3] Oncology Translational Medicine, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139, USA. ^[4] Computation Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. ^[5] Medical Oncology, Vall d'Hebron Institute of Oncology, Pg Vall d'Hebron, 119-129, Barcelona 08035, Spain. ^[6] Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet s/n, 08916 Badalona, Spain; Pangaea Biotech SL, Laboratorio de Oncología, Hospital Universitario Quirón Dexeus, C/ Sabino Arana 5-19, 08028 Barcelona, Spain. ^[7] Pangaea Biotech SL, Laboratorio de Oncología, Hospital Universitario Quirón Dexeus, C/ Sabino Arana 5-19, 08028 Barcelona, Spain. ^[8] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. ^[9] Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. ^[10] Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Electronic address: scaltrim@mskcc.org. ^[11] Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Electronic address: baselgaj@mskcc.org. ^[12]

主题词动物(Animals);癌, 鳞状细胞(Carcinoma, Squamous Cell);细胞系, 肿瘤(Cell Line, Tumor);I类磷脂酰肌醇3-激酶类(Class I Phosphatidylinositol 3-Kinases);抗药性, 肿瘤(Drug Resistance, Neoplasm);食管肿瘤(Esophageal Neoplasms);头颈部肿瘤(Head and Neck Neoplasms);人类(Humans);小鼠(Mice);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);蛋白激酶C(Protein Kinase C);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质类(Proto-Oncogene Proteins);受体蛋白质酪氨酸激酶类(Receptor Protein-Tyrosine Kinases);信号传导(Signal Transduction);TOR丝氨酸-苏氨酸激酶(TOR Serine-Threonine Kinases);噻唑类(Thiazoles);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)

DOI 10.1016/j.ccell.2015.03.010

PMID 25873175

发布时间 2022-12-07

检索历史清除

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Cancer cell

相似文献

Cancer cell

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Cancer cell

相似文献

Cancer cell

相关期刊

检索历史清除